Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.67 HKD
Change Today +0.01 / 1.52%
Volume 2.4M
775 On Other Exchanges
Symbol
Exchange
Hong Kong
OTC US
Frankfurt
As of 4:01 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ck life sciences intl hldgs (775) Snapshot

Open
$0.67
Previous Close
$0.66
Day High
$0.68
Day Low
$0.66
52 Week High
06/3/15 - $0.98
52 Week Low
08/25/15 - $0.59
Market Cap
6.4B
Average Volume 10 Days
7.3M
EPS TTM
$0.03
Shares Outstanding
9.6B
EX-Date
05/20/15
P/E TM
20.9x
Dividend
$0.0080
Dividend Yield
1.19%
Current Stock Chart for CK LIFE SCIENCES INTL HLDGS (775)

Related News

No related news articles were found.

ck life sciences intl hldgs (775) Related Businessweek News

No Related Businessweek News Found

ck life sciences intl hldgs (775) Details

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, engages in the research and development, manufacture, commercialization, marketing, and sale of health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and contract manufactures complementary healthcare medicines and produces non-sterile prescription and over-the-counter medicines. The company is also involved in licensing registration activities and the importation of finished agricultural goods; holding land and building; financing and trustee activities; investment in financial instruments, as well as vineyards and wineries; trading biotechnology products and nutritional supplements; and the manufacture, wholesale, retail, and distribution of nutraceutical products. In addition, it distributes turf management machinery, hardware, equipment, and accessories, as well as chemicals and professional pest products; produces, refines, and distributes salt products; and provides services in the research and development of bio-technology and life sciences technology products. The company’s products include emulsifiable concentrates, suspension concentrates, aqueous solutions, coated granules, powders, and amination based reactions for crop protection; and pharmaceutical products, such as Tetrodotoxin and POL-103A that are in advanced stages of clinical development for the treatment of cancer, as well as cosmetics. Further, it engages in the discovery, development, manufacture, and commercialization of drug products to treat pain; development of Melanoma vaccine, which is in Phase III clinical trial; and supply of raw materials for various segments. The company is headquartered in Tai Po, Hong Kong.

1,695 Employees
Last Reported Date: 08/4/15

ck life sciences intl hldgs (775) Top Compensated Officers

Chief Operating Officer, Vice President, Comp...
Total Annual Compensation: $9.7M
Chief Scientific Officer, Vice President and ...
Total Annual Compensation: $6.2M
Compensation as of Fiscal Year 2014.

ck life sciences intl hldgs (775) Key Developments

Ck Life Sciences Int'l., (Holdings) Inc. Announces Unaudited Consolidated Financial Results for the Six Months Ended June 30, 2015

CK Life Sciences Int'l., (Holdings) Inc. announced unaudited consolidated financial results for the six months ended June 30, 2015. For the six months, the company reported turnover HKD 2,449,263,000 against HKD 2,416,792,000 a year ago. Profit before taxation was HKD 220,699,000 against HKD 169,965,000 a year ago. Profit attributable to shareholders of the company was HKD 190,806,000 or 1.99 cents per basic and diluted share against HKD 146,608,000 or 1.53 cents per basic and diluted share a year ago. Net cash from operating activities was HKD 79,061,000 against HKD 140,933,000 a year ago.

CK Life Sciences Int'l., (Holdings) Inc. to Report First Half, 2015 Results on Jul 21, 2015

CK Life Sciences Int'l., (Holdings) Inc. announced that they will report first half, 2015 results on Jul 21, 2015

CK Life Sciences Int'l., (Holdings) Inc., Board Meeting, Jul 21, 2015

CK Life Sciences Int'l., (Holdings) Inc., Board Meeting, Jul 21, 2015. Agenda: To approve the release of the interim results of the company and its subsidiaries for the six months ended 30 June, 2015; and to consider the payment of an interim dividend.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
775:HK $0.67 HKD +0.01

775 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CK Hutchison Holdings Ltd $104.60 HKD +0.70
Henderson Land Development Co Ltd $48.30 HKD -0.50
Real Nutriceutical Group Ltd $1.45 HKD +0.01
TOM Group Ltd $1.60 HKD +0.09
View Industry Companies
 

Industry Analysis

775

Industry Average

Valuation 775 Industry Range
Price/Earnings 20.9x
Price/Sales 1.3x
Price/Book 1.4x
Price/Cash Flow 17.3x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CK LIFE SCIENCES INTL HLDGS, please visit www.ck-lifesciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.